ZHOU YING
Chief pharmacist;
Deputy director of Department of Pharmacy in Peking University First Hospital; Associate professor in Peking University School of Pharmaceutical Sciences
Research Areas
Antibiotics and pediatric clinical pharmacology
Population pharmacokinetics
Evidence-based pharmacy
Education & Positions
Bachelor of Pharmacy, Peking University Health Science Center, Beijing, China, 1994
Pharmacist, Peking University First Hospital, Beijing, China, 1994
Pharmacist-in-charge, Peking University First Hospital, Beijing, China, 1999
Visiting Scholar, Toyama medical and pharmaceutical university, Toyama, Japan, 2005
Master of Clinical Pharmacy, Peking University, Beijing, China, 2006
Deputy director of the Pharmacist, Peking University First Hospital, Beijing, China, 2006
Master of Management, TsingHua University, Beijing, China, 2010
Chief pharmacist, Peking University First Hospital, Beijing, China, 2011
Faculty Accolades
Excellence Award, Monitoring of adverse drug reactions in Beijing, 1994
Special Excellence Award, Monitoring of adverse drug reactions in Beijing Special Award of Excellence, 1997
Special Excellence Award, Monitoring of adverse drug reactions in Beijing Special Award of Excellence, 1998
The Third Prize of Outstanding Paper, Pharmacy Academic Conference in Beijing, 2005
Outstanding information officer, Ministry of Health clinical use of antibiotics Monitoring Network, 2006
Excellence Award, Ministry of Health clinical use of antibiotics reasonable evaluation Monitoring Network, 2006
Outstanding member units award (first place), Ministry of Health clinical use of antibiotics monitoring network, 2007
Outstanding writing award (first prize), Chinese Pharmaceutical Associations’national depth and promotion of clinical pharmacy drug conference calendar, 2007
Excellence Award (first place), Ministry of Health clinical use of antibiotics monitoring network monitoring, 2008
The Third Prize of Outstanding Paper, Pharmacy Academic Conference in Beijing, 2008
The Second Prize of Outstanding Paper, Chinese Pharmacological Society of Clinical Pharmacology Professional Committee of the Eleventh National Academic Conference of Clinical Pharmacology, 2008
The first session of the Chinese Hospital Pharmacy Award - Young Pharmacist Award of Excellence, 2009
American Chemical Society Akron Section Award, 2010
Mr. and Mrs. Sun Chan Memorial Award in Organic Chemistry, 2012
The Second Prize Award, Chinese Pharmaceutical Science and Technology (3rd of 4), 2012
The third prize of Hua Xia Medical Science and Technology Award of China International Exchange and Promotive Association for Medical and Health Care (4th of 6), 2013
The first prize of outstanding papers of The fourth national academic conference on therapeutic drug monitoring, 2014
Arthur C. Cope Scholar Award, 2015
American Association for the Advancement of Science (AAAS) Fellow, 2015
Paul Marks Prize in Cancer Research, 2017
Research Interests
Our team mainly focuses on the management of antibiotics among patients, especially pediatric population. We employ population pharmacokinetics (PPK) to assist Therapeutic Drug Monitoring (TDM). Up to now, we have established PPK models of vancomycin, voriconazole and tacrolimus in different groups and applied in clinical practice. Moreover, evidence-based studies are ongoing with regard to rare diseases and orphan drugs.
Grants and Fundings
Ministry of Science and Technology “13th Five-Year” project for Major New Drugs: Sub-topic 8 on Pediatric Drugs and Key Technology Research and Discovery: Research and Discovery of Pediatric Drugs in Urgent Need and Industrialization Platforms; 2018ZX09721003-008, 2018-2022, RMB 22926.83, In Process, Principal
Beijing Pharmaceutical Association Hospital Pharmacy Research Project, “Clinical Pharmacists' Role in DRC Payment Method Reform and Implementation of Clinical Pathway”, 2017/12-2018/11, RMB 10,000, Principal.
Beijing Municipal Committee of Science and Technology, “Capital Clinical Features Application Research”, Z151100004015044, A new model of individualized treatment of oxcarbazepine in children with epilepsy: the application of pharmacogenomics and the establishment of a PK/PD chain model, 2015/07- 2018/07, RMB 225,000, In Process, Principal
National Science and Technology Support Plan for the Twelfth Five-Year Plan, 2013BAI06B04Y023055, Research and Application of Evaluation of Safety and Rational Drug Use and Intervention Techniques - Comprehensive Evaluation of Clinically Used Large Variety Drugs: A Comprehensive Evaluation Study of Insulin in Lisu, 2013/05-2013/12, RMB 5,000, Completed, Principal.
National Key Projects for the 11th Five-year Science and Technology Support Program, 2009BAI76B031000, Evaluation and research on the rational use of basic medicines in basic medical institutions. Sub-topic: Preparation of general public essential drug safety medication science materials, 2010/06-2010/08, RMB 5000, Completed, Principal.
WHO Topics, WPhchn 100461, Establishment of Evaluation Index System for Rational Drug Use of Antimicrobial Drugs and Comprehensive Evaluation Methodology - Sub-topics Establishment of Vancomycin and Meropenem Evaluation System, 2010/01-2011/12, RMB 30,000, Completed, Principal.
National Science and Technology Support Program, 2006BAI01A02, Sub-topics of the early diagnosis and comprehensive treatment technology system for coronary heart disease Sub-topic: supervision and management work, 2007/07-2010/12, RMB 100,000, Completed, Principal.
The National Natural Science Foundation of China, 81273592, PEAR1 receptor genetic polymorphism and antithrombotic drug effect correlation studies, 2013/01-2016/12, RMB 700,000, Completed, Participator.
Peking University-Tsinghua University Life Science Joint Center Clinical Talent Cultivation Project, 2013500006, A New Mode of Cyclosporin A Treatment for Children with Nephrotic Syndrome—Personalized Treatment with Population Pharmacokinetics, 2013/01-2013/12, RMB 150,000, Completed, Principal.
Pharmacy Research Project of Beijing Pharmaceutical Association Hospital, “Study on the Pharmacokinetics of Cyclosporine in Patients with Bone Marrow Transplantation”, 2007/12-2008/08, RMB 10,000, Completed, Principal.
Publications (Corresponding Author with a ‘*’)
Kunming Pan, Lingyun Ma, Qian Xiang, Xueying Li, Haixia Li, Ying Zhou*, Li Yang*, Yimin Cui. Vancomycin-associated acute kidney injury: a cross-sectional study from a single center in China. PLoS One. 2017 Apr 20;12(4):e0175688.
ZHOU Shuang，SHENG Xiao-yan，XIANG Qian，WANG Zi-ning，ZHOU Ying*，CUI Yi-min. Comparing the effectiveness of pharmacist-managed warfarin anticoagulation with other models: a systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics,2016Dec;41(6):602-611
Ruirui Li, Xiaoyan Sheng , Lingyue Ma, Hongxin Yao, Lixin Cai, Chaoyang Chen, Sainan Zhu, Ying Zhou*, Ye Wu, Yimin Cui. Saliva and Plasma Monohydroxycarbam-azepine Concentrations in Pediatric Patients with Epilepsy. Ther Drug Monit.2016 Jun;38(3):365-70.
Zhao L, Sheng X, Zhou S, Yang T, Ma L,Zhou Y*, Cui Y. Metformin versus insulin for gestational diabetes mellitus: a meta-analysis. Br J Clin Pharmacol. 2015 80(5):1224-34
Zhou Y, Ma LY, Zhao X, Tian SH, Sun LY, Cui YM. Impact of pharmacist intervention on antibiotic use and prophylactic antibiotic use in urology clean operations. J Clin Pharm Ther. 2015;40(4):404-8.
Zhou Y, Sheng XY, Xu JY, Bi SS, Lu W, Cui YM. Population pharmacokinetic study of Cyclosporine in the hematopoietic stem cell transplant recipients. Int J Clin Pharmacol Ther. 2013，51(7)：568-575.
Ying Zhou, Yimin Cui, Xia Zhao, Yong Huo, Zhao hongNie, Min Zhao, Zhixin Guo, He Sun. The Safety and Tolerance of Herbal Anti-Angina Drug Compound Danshen Droplet Pill in Healthy Volunteers. Pharmacology & Pharmacy, 2013, 4: 490-495.
Ying Zhou, Peihong Sun, Yuwang Liu, Xia Zhao, Lei Meng, Yimin Cui*. Safety and Pharmacokinetic Studies of Silodosin, a New α1A-Adrenoceptor Selective Antagonist, in Healthy Chinese Male Subjects. Biological&Pharmaceutical Bulletin, 2011, 34(8): 1240.
Yang T, Lu M, Ma L,Zhou Y, Cui Y. Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. Eur J Clin Pharmacol. 2015; 71(11):1325-1332
Wang Z, Xiang Q, Cui Y, Zhao X, Zhou Y. The Influence of UGT 2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug Metab Pharmaco. 2013; 28(3):239-43.
Min Lu, Yi Min Cui, Ying Zhou. Possible Metformin-induced toe nails disorder. Pharmacology & Pharmacy, 2013, 4: 275-276.
Xiang Q, Yu F, LV J, Zhao X, Han J, Zhou Y, DU S, Zhao MH, Zhang H, Cui YM, Wang HY. Integration of genetic and clinical data to analyze pharmacokinetic profile of mycophenolic acid in a population of Chinese patients with glomerular disease. Int Res J Pharm Pharmacol. 2013; 3(2): 19-28.
Wang Z, Xiang Q, Cui Y*, Zhao X,Zhou Y. The Influence of UGT 2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug Metab Pharmaco . 2013;28(3):239-43.
Zining Wang, Yimin Cui*, Xiaowen Chen, Huilin Zhang, Xia Zhao, Ying Zhou. Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects. Acta Pharmacologica Sinica. 2012, 33:1395-1400.
Qian Xiang, Yimin Cui*, Xia Zhao, Yan Liang, Ying Zhou. The Influence of MDR1 G2677T/ A Genetic Polymorphisms on the Pharmacokinetics of Repaglinide in Healthy Chinese Volunteers. Pharmacology, 2012, 89: 105.
Peihong Sun, Xia Zhao, Ying Zhou, Yan Liang, Huilin Zhang, Yimin Cui*, Jining Tao. Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteer. Acta Pharmacologica Sinica, 2011, 32(12): 1549.
Qian Xiang, Xia Zhao, Ying Zhou, Jingli Duan, Yimin Cui*. Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety. The Journal of Clinical Pharmacology, 2010, 50(6): 659.
Xia Zhao, Yuwang Liu, Junyu Xu, Dan Zhang, Ying Zhou, Jingkai Gu, Yimin Cui*. Determination of silodosin in human plasma by liquid chromatography-tandemmass spectrometry. Journal of Chromatography B, 2009, 877(29):3724-3728.
Zhao X, Sun PH，Zhou Y，Liu YW，Zhang HL，Mueck W，Kubitza D，Bauer RJ，Zhang H，Cui YM*. Safety, pharmacokinetics and pharmacodynamics ofsingle/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol , 2009, 68(1):77-88.
Cui YM, Zhou Y, Choo HT, Alan X P, Eunice Y, Kwee PY, Amanda J. Long. Atomoxetine Pharmacokinetics in Healthy Chinese Subjects and effect of the CYP2D6*10 allele. Br J Clin Pharmacol, 2007, 64:445-449.